Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
This study provides valuable insights into the impact of genetic variations on the response rate of TCZ in COVID-19 patients. The GA genotype for FCGR2A rs1801274 was associated with poor treatment outcomes.
Authors
- Hamed Ghoshouni (ORCID: https://orcid.org/0000-0001-8949-2256)
- Fatemeh Aghaeimeybodi
- Maedeh Arshadi (ORCID: https://orcid.org/0000-0001-7696-5042)
- Samira Asadollahi (ORCID: https://orcid.org/0000-0002-6712-0504)
- Nastaran Injinari (ORCID: https://orcid.org/0000-0001-5524-5388)
- Mohammad Hasan Sheikhha (ORCID: https://orcid.org/0000-0002-3734-8970)
- Nasim Namiranian (ORCID: https://orcid.org/0000-0002-5133-6204)
- Saeedeh Sadat Hosseini
- Fateme Sefid (ORCID: https://orcid.org/0000-0003-0867-9305)
- Fatemeh Soltani (ORCID: https://orcid.org/0009-0006-3694-657X)
Institutions
- Iran University of Medical Sciences (IR)
- Shahid Sadoughi University of Medical Sciences and Health Services (IR)
- Shaheed Rajaei Cardiovascular Medical and Research Center (IR)
- Diabetes Research Center
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1186/s12879-024-10073-0
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00